BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

St. Paul's Hospital
613-1081 Burrard Street
Vancouver, BC
Canada V6Z 1Y6

Tel 604.806.8477
Fax 604.806.8464
www.cfenet.ubc.ca

November 15, 2019

RE: Bictegravir-emtricitabine-tenofovir alafenamide (Biktarvy®) on BC-CfE Formulary

Dear Antiretroviral Prescriber:

Bictegravir-emtricitabine-tenofovir alafenamide (Biktarvy®) is now available through the BC-CfE Drug Treatment Program. Biktarvy® is approved by Health Canada for use as a complete regimen for the treatment of HIV-1 infection in adults with no known resistance to the components of the product. Biktarvy® has demonstrated non-inferiority to dolutegravir-based triple regimens as initial therapy. Biktarvy® has also been found efficacious in selected groups of treatment-experienced HIV-1 infected adults. Safety and effectiveness of Biktarvy has not been established in women during pregnancy, or in pediatric patients less than 18 years of age.

Dosing and administration

- Biktarvy® is recommended at a dose of one tablet orally once daily with or without food.
- Biktarvy® is not recommended in individuals with estimated creatinine clearance less than 30 mL per minute.
- Biktarvy® should not be taken at the same time as aluminum or magnesium antacids.
- Biktarvy® is contraindicated with strong Cytochrome P450 metabolic inducers, including rifampin and St. John's Wort.

New prescription requests

- New prescriptions for Biktarvy®, including switches from other antiretroviral products, require submission of an HIV Drug Treatment Program Prescription Request Form (available at www.cfenet.ubc.ca). Prescribers are expected to provide justification for such drug switches accompanying the prescription.

For advice about this medication, please call St. Paul's Hospital Ambulatory Pharmacy at 1-888-511-6222.

Sincerely,

Val Montessori, MD, FRCPC
Co-Chair, Committee for Drug Evaluation and Therapy
BC Centre for Excellence in HIV/AIDS

Julio S.G. Montaner, OC, OBC, MD
Executive Director and Physician-in-Chief
BC Centre for Excellence in HIV/AIDS